Protocol Ledger

NCT06345079 · Phase II · RECRUITING

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Interventional Phase II clinical trial protocol NCT06345079 sponsored by Australasian Gastro-Intestinal Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-14 Enrollment: 78 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06345079
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)78 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06345079
Protocol FieldVerified Registry Value
NCT IdentifierNCT06345079
Consolidated Lead SponsorAustralasian Gastro-Intestinal Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment78 participants (ESTIMATED)
Registered Start Date2024-10-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06345079
Hospital Research SiteLocationSite Profile
Peter MacCallum Cancer CentreMelbourne, AustraliaOpen Hospital Dossier ->
Cross Cancer InstituteEdmonton, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI